NMD Pharma A/S

https://www.nmdpharma.com

LinkedIn: https://www.linkedin.com/company/nmdpharma

NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in-vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received seed financing from Novo Holdings, Lundbeckfonden Emerge and Capnova in 2016, and in 2018 raised a €38 million Series A financing, led by new investor INKEF Capital, together with new investor Roche Venture Fund and existing investors Novo Holdings and Lundbeckfonden Emerge. *

	Start	2015-01-01 established (s-off)
	Predecessor	Aarhus University
	Industry	CLC-1 inhibitor
	Industry 2	drug development
	Person	Pedersen, Thomas Holm (NMD Pharma 201803 CEO)

	Region	Århus (Aarhus)
	Country	Denmark
	Street	82 Palle Juul-Jensens Boulevard
	City	8200 Aarhus N
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: NMD Pharma A/S. (2/15/22). "Press Release: NMD Pharma Raises €35 Million in a New Financing". Aarhus.

		Record changed: 2024-02-12